Utilizing Patient Experiences to Advance T Regulatory Cells in the Treatment of Autoimmune Diseases

• Manufacturing ex vivo polyclonal Tregs to secure authorisations of Treg cell therapies in GvHD and T1D
• Analysing clinical trial patient immune systems to generate novel cell therapies in the clinic
• Preparing novel autologous and allogenic Tregs to facilitate the effective scale up of manufacturing and treatment delivery to expand patient access

Speakers:

Piotr Trzonkowski

Chief Executive Officer

PolTREG/Immuthera